Company profile
Merck & Co., Inc.
NYSE: MRK · Healthcare · Drug Manufacturers - General
#12 of 1,422 Healthcare companies by revenue44th-percentile growth
EA Score
84B+FH 90DQ 84GM 60SS 99
v0.1 · 65/100 weight · provisional
↑ market scale, workforce scale · ↓ revenue growth (YoY), 3-yr revenue growth
Methodology →Revenue TTM
$65.6B
Rev growth YoY (TTM)
+2.5%
Net income (FY)
$18.3B
Employees
75,000
as of 2026-08-04
Market cap
$315.4B
as of 2026-08-04
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$65.0B$65.0B2025
Net income$18.3B$18.3B2025
Total assets$136.9B$136.9B2025
Equity$52.6B$52.6B2025
Revenue trend
FY2018 – FY2025 · USD
FY18
FY19
FY20
FY21
FY22
FY23
FY24
FY25
Revenue by segment
Filed disclosures · FY2025
By product
Pharmaceutical89%
Animal Health10%
Other Segments1%
By geography
UNITED STATES56%
EMEA22%
Latin America5%
Asia Pacific5%
International4%
JAPAN4%
The read
What is Merck & Co., Inc.’s revenue?
Merck & Co., Inc. booked $65.0B in FY2025 revenue, growing 1.3% year over year — about the middle of the pack among Healthcare companies we track, at a 28.1% net margin.
Peers · Healthcare
Johnson & Johnson80B+HCA Healthcare, Inc.78B+Eli Lilly and Company93APfizer Inc.76B+AbbVie Inc.81B+Bristol-Myers Squibb Company85ANeighbors
Union →Key facts
CEORobert Davis
SectorHealthcare
IndustryDrug Manufacturers - General
HeadquartersRahway, NJ
ExchangeNYSE: MRK
Employees75,000
IPO date1978-01-13
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.